J&J faces price and patent probe over TB drug in South Africa

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

J&J faces price and patent probe over TB drug in South Africa

Aerial view of Capetown, SOuth Africa
Cape Town

The drugmaker is reportedly accused of excessive pricing for anti-TB drug bedaquiline and patent evergreening

South Africa’s Competition Commission will investigate Johnson & Johnson over excessive pricing for a tuberculosis drug and patent evergreening, local media reported yesterday, September 14.

The US drugmaker has faced heavy criticism this year over its pricing and patent strategies for bedaquiline, which is used to treat drug-resistant TB.

South African officials are said to be concerned that South Africa is paying twice as much for the drug as other low- and middle-income countries.

The Health Justice Initiative (HJI), a non-profit organisation, announced the probe after a briefing from government officials.

A spokesperson for the Competition Commission confirmed the news to local media and said it would issue a full statement soon.

Bedaquiline prices fell this summer after J&J agreed to license patents to the Stop TB Partnership’s Global Drug Facility.

The Stop TB Partnership is a UN-backed organisation aimed at improving access to TB treatment.

That deal came after access to medicine campaigners targeted J&J over its efforts to extend patent protection on bedaquiline, which is set to expire in most countries this year.

Last month, the Stop TB Partnership revealed that prices for the drug fell by up to 55% as a result of the J&J licence.

J&J now charges most lower-income countries a headline price of $130 for a six-month course of the drug compared to the old figure of $289.

But South Africa doesn’t appear to be benefiting from the slide in prices.

Under the Ministry of Health’s latest deal with J&J, concluded last month, South Africa will pay R5,500 ($288.62) for a six-month course.

Fatima Hassan, a prominent health lawyer and founder of the HJI, called the news “unprecedented and welcome”.

“It is time our country stands up to the bullying of multinational pharmaceutical corporations, in all its forms,” she said.

A spokesperson for J&J said: the company had a "longstanding commitment" to South Africa’s fight against multidrug-resistant tuberculosis (MDR-TB).

"Today, all patients in South Africa who require bedaquiline, our medicine for MDR-TB, have access to it thanks to our collaboration with the government of South Africa and other stakeholders, which has contributed to a steady decline in TB incidence.

"The company will cooperate fully with the Competition Commission in its inquiry, and cannot comment further while this is ongoing," the spokesperson said.

more from across site and SHARED ros bottom lb

More from across our site

Ulla Loreth, IP counsel at Puma in Germany, says logistics intermediaries can no longer turn a blind eye after ‘game-changing’ judgment in the fight against counterfeits
Ahmed Hankawi joins us for our ‘Five minutes with’ series to discuss his approach to cases, and why he admires lawyers who help develop the next generation
Mercedes Bullrich looks back on her career and explains how a life shaped by fresh starts will help her develop a new firm
AI
Leaders at four firms share their hiring approach, including whether AI knowledge is a must-have for new staff
McKool Smith and Licks Attorneys are acting in the dispute, which alleges infringement of patents covering video-related technologies
Legacy firm Allen & Overy agreed a high-profile tie-up with US firm Shearman & Sterling in May last year
News of Verizon settling its lawsuit with Headwater Research and a copyright setback for AI firm Perplexity at a New York court were also among the top talking points
IPH, which owns several IP businesses in the APAC and Canada, reported a 16.5% increase in revenue and 13% jump in profit after tax
With Ireland’s government re-engaging with the idea of a UPC referendum, it provides a chance to improve the system further
US-based company says appointment of Jorge Ordonez shows its momentum as a private-equity-backed platform expanding in the IP services market
Gift this article